Browsing by Subject "Rhinitis"

Sort by: Order: Results:

Now showing items 1-19 of 19
  • Calderon, M. A.; Demoly, P.; Casale, T.; Akdis, C. A.; Bachert, C.; Bewick, M.; Bilo, B. M.; Bohle, B.; Bonini, S.; Bush, A.; Caimmi, D. P.; Canonica, G. W.; Cardona, V.; Chiriac, A. M.; Cox, L.; Custovic, A.; De Blay, F.; Devillier, P.; Didier, A.; Di Lorenzo, G.; Du Toit, G.; Durham, S. R.; Eng, P.; Fiocchi, A.; Fox, A. T.; van Wijk, R. Gerth; Gomez, R. M.; Haahtela, Tari Markku Kallevi; Halken, S.; Hellings, P. W.; Jacobsen, L.; Just, J.; Tanno, L. K.; Kleine-Tebbe, J.; Klimek, L.; Knol, E. F.; Kuna, P.; Larenas-Linnemann, D. E.; Linneberg, A.; Matricardi, M.; Malling, H. J.; Moesges, R.; Mullol, J.; Muraro, A.; Papadopoulos, N.; Passalacqua, G.; Pastorello, E.; Pfaar, O.; Price, D.; Rodriguez del Rio, P.; Rueff, R.; Samolinski, B.; Scadding, G. K.; Senti, G.; Shamji, M. H.; Sheikh, A.; Sisul, J. C.; Sole, D.; Sturm, G. J.; Tabar, A.; Van Ree, R.; Ventura, M. T.; Vidal, C.; Varga, E. M.; Worm, M.; Zuberbier, T.; Bousquet, J. (2016)
    Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
  • Bousquet, J.; Hellings, P. W.; Agache, I.; Bedbrook, A.; Bachert, C.; Bergmann, K. C.; Bewick, M.; Bindslev-Jensen, C.; Bosnic-Anticevitch, S.; Bucca, C.; Caimmi, D. P.; Camargos, P. A. M.; Canonica, G. W.; Casale, T.; Chavannes, N. H.; Cruz, A. A.; De Carlo, G.; Dahl, R.; Demoly, P.; Devillier, P.; Fonseca, J.; Fokkens, W. J.; Guldemond, N. A.; Haahtela, T.; Illario, M.; Just, J.; Keil, T.; Klimek, L.; Kuna, P.; Larenas-Linnemann, D.; Morais-Almeida, M.; Mullol, J.; Murray, R.; Naclerio, R.; O'Hehir, R. E.; Papadopoulos, N. G.; Pawankar, R.; Potter, P.; Ryan, D.; Samolinski, B.; Schunemann, H. J.; Sheikh, A.; Simons, F. E. R.; Stellato, C.; Todo-Bom, A.; Tomazic, P. V.; Valiulis, A.; Valovirta, E.; Ventura, M. T.; Wickman, M.; Young, I.; Yorgancioglu, A.; Zuberbier, T.; Aberer, W.; Akdis, C. A.; Akdis, M.; Annesi-Maesano, I.; Ankri, J.; Ansotegui, I. J.; Anto, J. M.; Arnavielhe, S.; Asarnoj, A.; Arshad, H.; Avolio, F.; Baiardini, I.; Barbara, C.; Barbagallo, M.; Bateman, E. D.; Beghe, B.; Bel, E. H.; Bennoor, K. S.; Benson, M.; Bialoszewski, A. Z.; Bieber, T.; Bjermer, L.; Blain, H.; Blasi, F.; Boner, A. L.; Bonini, M.; Bonini, S.; Bosse, I.; Bouchard, J.; Boulet, L. P.; Bourret, R.; Bousquet, P. J.; Braido, F.; Briggs, A. H.; Brightling, C. E.; Brozek, J.; Buhl, R.; Bunu, C.; Burte, E.; Bush, A.; Caballero-Fonseca, F.; Calderon, M. A.; Camuzat, T.; Cardona, V.; Carreiro-Martins, P.; Carriazo, A. M.; Carlsen, K. H.; Carr, W.; Cepeda Sarabia, A. M.; Cesari, M.; Chatzi, L.; Chiron, R.; Chivato, T.; Chkhartishvili, E.; Chuchalin, A. G.; Chung, K. F.; Ciprandi, G.; Correia de Sousa, J.; Cox, L.; Crooks, G.; Custovic, A.; Dahlen, S. E.; Darsow, U.; Dedeu, T.; Deleanu, D.; Denburg, J. A.; De Vries, G.; Didier, A.; Dinh-Xuan, A. T.; Dokic, D.; Douagui, H.; Dray, G.; Dubakiene, R.; Durham, S. R.; Du Toit, G.; Dykewicz, M. S.; Eklund, P.; El-Gamal, Y.; Ellers, E.; Emuzyte, R.; Farrell, J.; Wagner, A. Fink; Fiocchi, A.; Fletcher, M.; Forastiere, F.; Gaga, M.; Gamkrelidze, A.; Gemicioglu, B.; Gereda, J. E.; van Wick, R. Gerth; Gonzalez Diaz, S.; Grisle, I.; Grouse, L.; Gutter, Z.; Guzman, M. A.; Hellquist-Dahl, B.; Heinrich, J.; Horak, F.; Hourihane, J. O'. B.; Humbert, M.; Hyland, M.; Iaccarino, G.; Jares, E. J.; Jeandel, C.; Johnston, S. L.; Joos, G.; Jonquet, O.; Jung, K. S.; Jutel, M.; Kaidashev, I.; Khaitov, M.; Kalayci, O.; Kalyoncu, A. F.; Kardas, P.; Keith, P. K.; Kerkhof, M.; Kerstjens, H. A. M.; Khaltaev, N.; Kogevinas, M.; Kolek, V.; Koppelman, G. H.; Kowalski, M. L.; Kuitunen, M.; Kull, I.; Kvedariene, V.; Lambrecht, B.; Lau, S.; Laune, D.; Le, L. T. T.; Lieberman, P.; Lipworth, B.; Li, J.; Carlsen, K. C. Lodrup; Louis, R.; Lupinek, C.; MacNee, W.; Magar, Y.; Magnan, A.; Mahboub, B.; Maier, D.; Majer, I.; Malva, J.; Manning, P.; De Manuel Keenoy, E.; Marshall, G. D.; Masjedi, M. R.; Mathieu-Dupas, E.; Maurer, M.; Mavale-Manuel, S.; Melen, E.; Melo-Gomes, E.; Meltzer, E. O.; Mercier, J.; Merk, H.; Miculinic, N.; Mihaltan, F.; Milenkovic, B.; Millot-Keurinck, J.; Mohammad, Y.; Momas, I.; Mosges, R.; Muraro, A.; Namazova-Baranova, L.; Nadif, R.; Neffen, H.; Nekam, K.; Nieto, A.; Niggemann, B.; Nogueira-Silva, L.; Nogues, M.; Nyembue, T. D.; Ohta, K.; Okamoto, Y.; Okubo, K.; Olive-Elias, M.; Ouedraogo, S.; Paggiaro, P.; Pali-Schoell, I.; Palkonen, S.; Panzner, P.; Papi, A.; Park, H. S.; Passalacqua, G.; Pedersen, S.; Pereira, A. M.; Pfaar, O.; Picard, R.; Pigearias, B.; Pin, I.; Plavec, D.; Pohl, W.; Popov, T. A.; Portejoie, F.; Postma, D.; Poulsen, L. K.; Price, D.; Rabe, K. F.; Raciborski, F.; Roberts, G.; Robalo-Cordeiro, C.; Rodenas, F.; Rodriguez-Manas, L.; Rolland, C.; Roman Rodriguez, M.; Romano, A.; Rosado-Pinto, J.; Rosario, N.; Rottem, M.; Sanchez-Borges, M.; Sastre-Dominguez, J.; Scadding, G. K.; Scichilone, N.; Schmid-Grendelmeier, P.; Serrano, E.; Shields, M.; Siroux, V.; Sisul, J. C.; Skrindo, I.; Smit, H. A.; Sole, D.; Sooronbaev, T.; Spranger, O.; Stelmach, R.; Sterk, P. J.; Strandberg, T.; Sunyer, J.; Thijs, C.; Triggiani, M.; Valenta, R.; Valero, A.; van Eerd, M.; van Ganse, E.; van Hague, M.; Vandenplas, O.; Varona, L. L.; Vellas, B.; Vezzani, G.; Vazankari, T.; Viegi, G.; Vontetsianos, T.; Wagenmann, M.; Walker, S.; Wang, D. Y.; Wahn, U.; Werfel, T.; Whalley, B.; Williams, D. M.; Williams, S.; Wilson, N.; Wright, J.; Yawn, B. P.; Yiallouros, P. K.; Yusuf, O. M.; Zaidi, A.; Zar, H. J.; Zernotti, M. E.; Zhang, L.; Zhong, N.; Zidarn, M. (2016)
    The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
  • Bosnic-Anticevich, Sinthia; Costa, Elisio; Menditto, Enrica; Lourenco, Olga; Novellino, Ettore; Bialek, Slawomir; Briedis, Vitalis; Buonaiuto, Roland; Chrystyn, Henry; Cvetkovski, Biljana; Di Capua, Stefania; Kritikos, Vicky; Mair, Alpana; Orlando, Valentina; Paulino, Ema; Salimäki, Johanna; Söderlund, Rojin; Tan, Rachel; Williams, Dennis M.; Wroczynski, Piotr; Agache, Ioana; Ansotegui, Ignacio J.; Anto, Josep M.; Bedbrook, Anna; Bachert, Claus; Bewick, Mike; Bindslev-Jensen, Carsten; Brozek, Jan L.; Canonica, Giorgio Walter; Cardona, Victoria; Carr, Warner; Casale, Thomas B.; Chavannes, Niels H.; de Sousa, Jaime Correia; Cruz, Alvaro A.; Czarlewski, Wienczyslawa; De Carlo, Giuseppe; Demoly, Pascal; Devillier, Philippe; Dykewicz, Mark S.; Gaga, Mina; El-Gamal, Yehia; Fonseca, Joao; Fokkens, Wytske J.; Antonieta Guzman, Maria; Haahtela, Tari; Hellings, Peter W.; Illario, Maddalena; Carlos Ivancevich, Juan; Just, Jocelyne; Kaidashev, Igor; Khaitov, Musa; Khaltaev, Nikolai; Keil, Thomas; Klimek, Ludger; Kowalski, Marek L.; Kuna, Piotr; Kvedariene, Violeta; Larenas-Linnemann, Desiree E.; Laune, Daniel; Le, Lan T. T.; Carlsen, Karin C. Lodrup; Mahboub, Bassam; Maier, Dieter; Malva, Joao; Manning, Patrick J.; Morais-Almeida, Mario; Moesges, Ralph; Mullol, Joaquim; Munter, Lars; Murray, Ruth; Naclerio, Robert; Nannazova-Baranove, Leyla; Nekann, Kristof; Nyembue, Tshipukane Dieudonne; Okubo, Kimi; O'Hehir, Robyn E.; Ohta, Ken; Okamoto, Yoshitaka; Onorato, Gabrielle L.; Palkonen, Susanna; Panzner, Petr; Papadopoulos, Nikolaos G.; Park, Hae-Sim; Pawankar, Ruby; Pfaar, Oliver; Phillips, Jim; Plavec, Davor; Popov, Todor A.; Potter, Paul C.; Prokopakis, Emmanuel P.; Roller-Wirnsberger, Regina E.; Rottenn, Menachem; Ryan, Dermot; Sannolinski, Bolesfaw; Sanchez-Borges, Mario; Schunemann, Holger J.; Sheikh, Aziz; Sisul, Juan Carlos; Somekh, David; Stellato, Cristiana; To, Teresa; Todo-Bonn, Ana Maria; Tonnazic, Peter Valentin; Toppila-Salmi, Sanna; Valero, Antonio; Valiulis, Arunas; Valovirta, Errka; Ventura, Maria Teresa; Wagennnann, Martin; Wallace, Dana; Wasernnan, Susan; Wickman, Magnus; Yiallouros, Panayiotis K.; Yorgancioglu, Arzu; Yusuf, Osman M.; Zar, Heather J.; Zernotti, Mario E.; Zhang, Luo; Zidarn, Mihaela; Zuberbier, Torsten; Bousquet, Jean (2019)
    Pharmacists are trusted health care professionals. Many patients use over-the-counter (OTC) medications and are seen by pharmacists who are the initial point of contact for allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The Allergic Rhinitis and its Impact on Asthma (ARIA)-pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses), and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of allergic rhinitis. However, the ARIA-pharmacy ICP should be adapted to local healthcare environments/situations as regional (national) differences exist in pharmacy care.
  • Krischer, Jeffrey P.; Cuthbertson, David; Couluris, Marisa; Knip, Mikael; Virtanen, Suvi M. (2020)
    Aims/hypothesis This paper presents the relationship between islet autoantibodies, precursors of type 1 diabetes, and the development of persistent asthma, allergic rhinitis and atopic eczema. Methods A total of 2159 newborns who had a first-degree relative with type 1 diabetes and selected HLA genotypes were followed until the youngest participant reached 10 years of age. Islet cell antibodies (ICA) were detected using indirect immunofluorescence. Autoantibodies to insulin (IAA), GAD (GADA), the tyrosine phosphatase-related insulinoma-associated 2 molecule (IA-2A) and zinc transporter 8 (ZnT8A) were quantified with the use of specific radiobinding assays. As an ancillary study, the incidence of asthma, allergic rhinitis and eczema was assessed in 1106 of these children using the International Study of Asthma and Allergies in Childhood (ISAAC) core questionnaire when the children were 9-11 years old. HRs with 95% CIs were calculated to depict the incidence of these diseases following seroconversion to autoantibody positivity. Results The cumulative incidence of atopic eczema, allergic rhinitis and persistent asthma were 22%, 9% and 7.5%, respectively, by 9-11 years of age. The occurrence of diabetes-related autoantibodies showed a protective association with subsequently reported incidence of asthma and eczema. The incidence of rhinitis was not significantly related to the occurrence of IAA or GADA (statistical power was limited), but demonstrated the same inverse relationship as did the other diseases with ICA or when multiple autoantibodies first appeared together. Conclusions/interpretation The findings add evidence to the relationships between these atopic diseases and diabetes-related autoimmunity and also suggest that, for eczema, the interaction depends upon which autoantibody appeared first.
  • Hox, Valerie; Lourijsen, Evelijn; Jordens, Arnout; Aasbjerg, Kristian; Agache, Ioana; Alobid, Isam; Bachert, Claus; Boussery, Koen; Campo, Paloma; Fokkens, Wytske; Hellings, Peter; Hopkins, Claire; Klimek, Ludger; Makelä, Mika; Moesges, Ralph; Mullol, Joaquim; Pujols, Laura; Rondon, Carmen; Rudenko, Michael; Toppila-Salmi, Sanna; Scadding, Glenis; Scheire, Sophie; Tomazic, Peter-Valentin; Van Zele, Thibaut; Wagemann, Martin; van Boven, Job F. M.; Gevaert, Philippe (2020)
    Because of the inflammatory mechanisms of most chronic upper airway diseases such as rhinitis and chronic rhinosinusitis, systemic steroids have been used for their treatment for decades. However, it has been very well documented that-potentially severe-side-effects can occur with the accumulation of systemic steroid courses over the years. A consensus document summarizing the benefits of systemic steroids for each upper airway disease type, as well as highlighting the potential harms of this treatment is currently lacking. Therefore, a panel of international experts in the field of Rhinology reviewed the available literature with the aim of providing recommendations for the use of systemic steroids in treating upper airway disease.
  • Bousquet, J.; Onorato, G. L.; Bachert, C.; Barbolini, M.; Bedbrook, A.; Bjermer, L.; de Sousa, J. Correia; Chavannes, N. H.; Cruz, A. A.; Keenoy, E. De Manuel; Devillier, P.; Fonseca, J.; Hun, S.; Kostka, T.; Hellings, P. W.; Illario, M.; Ivancevich, J. C.; Larenas-Linnemann, D.; Millot-Keurinck, J.; Ryan, D.; Samolinski, B.; Sheikh, A.; Yorgancioglu, A.; Agache, I.; Arnavielhe, S.; Bewick, M.; Annesi-Maesano, I.; Anto, J. M.; Bergmann, K. C.; Bindslev-Jensen, C.; Bosnic-Anticevich, S.; Bouchard, J.; Caimmi, D. P.; Camargos, P.; Canonica, G. W.; Cardona, V.; Carriazo, A. M.; Cingi, C.; Colgan, E.; Custovic, A.; Dahl, R.; Demoly, P.; De Vries, G.; Fokkens, W. J.; Fontaine, J. F.; Gemicioglu, B.; Guldemond, N.; Gutter, Z.; Haahtela, T.; Hellqvist-Dahl, B.; Jares, E.; Joos, G.; Just, J.; Khaltaev, N.; Keil, T.; Klimek, L.; Kowalski, M. L.; Kull, I.; Kuna, P.; Kvedariene, V.; Laune, D.; Louis, R.; Magnan, A.; Malva, J.; Mathieu-Dupas, E.; Melen, E.; Menditto, E.; Morais-Almeida, M.; Mosges, R.; Mullol, J.; Murray, R.; Neffen, H.; O'Hehir, R.; Palkonen, S.; Papadopoulos, N. G.; Passalacqua, G.; Pepin, J. L.; Portejoie, F.; Price, D.; Pugin, B.; Raciborski, F.; Simons, F. E. R.; Sova, M.; Spranger, O.; Stellato, C.; Bom, A. Todo; Tomazic, P. V.; Triggiani, M.; Valero, A.; Valovirta, E.; VandenPlas, O.; Valiulis, A.; Van Eerd, M.; Ventura, M. T.; Wickman, M.; Young, I.; Zuberbier, T.; Zurkuhlen, A.; Senn, A. (2017)
    A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices.
  • MASK Study Grp (2018)
    Background: Collecting data on the localization of users is a key issue for the MASK (Mobile Airways Sentinel network: the Allergy Diary) App. Data anonymization is a method of sanitization for privacy. The European Commission's Article 29 Working Party stated that geolocation information is personal data. To assess geolocation using the MASK method and to compare two anonymization methods in the MASK database to find an optimal privacy method. Methods: Geolocation was studied for all people who used the Allergy Diary App from December 2015 to November 2017 and who reported medical outcomes. Two different anonymization methods have been evaluated: Noise addition (randomization) and k-anonymity (generalization). Results: Ninety-three thousand one hundred and sixteen days of VAS were collected from 8535 users and 54,500 (58. 5%) were geolocalized, corresponding to 5428 users. Noise addition was found to be less accurate than k-anonymity using MASK data to protect the users' life privacy. Discussion: k-anonymity is an acceptable method for the anonymization of MASK data and results can be used for other databases.
  • MASK Study Grp; Bousquet, J.; Bedbrook, A.; Czarlewski, W.; Haahtela, T.; Valovirta, E.; Vasankari, T.; Toppila-Salmi, S.; Salimäki, Johanna; Kuitunen, M.; Wallace, D. V. (2019)
    AimsMobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases.MethodsMASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients.StakeholdersInclude patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors.ResultsMASK is deployed in 23 countries and 17 languages. 26,000 users have registered.EU grants (2018)MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour).Lessons learnt(i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.
  • Bousquet, J.; Bedbrook, A.; Czarlewski, W.; Onorato, G. L; Arnavielhe, S.; Laune, D.; Mathieu-Dupas, E.; Fonseca, J.; Costa, E.; Lourenço, O.; Morais-Almeida, M.; Todo-Bom, A.; Illario, M.; Menditto, E.; Canonica, G. W; Cecchi, L.; Monti, R.; Napoli, L.; Ventura, M. T; De Feo, G.; Fokkens, W. J; Chavannes, N. H; Reitsma, S.; Cruz, A. A; da Silva, J.; Serpa, F. S; Larenas-Linnemann, D.; Fuentes Perez, J. M; Huerta-Villalobos, Y. R; Rivero-Yeverino, D.; Rodriguez-Zagal, E.; Valiulis, A.; Dubakiene, R.; Emuzyte, R.; Kvedariene, V.; Annesi-Maesano, I.; Blain, H.; Bonniaud, P.; Bosse, I.; Dauvilliers, Y.; Devillier, P.; Fontaine, J. F; Pépin, J. L; Pham-Thi, N.; Portejoie, F.; Picard, R.; Roche, N.; Rolland, C.; Schmidt-Grendelmeier, P.; Kuna, P.; Samolinski, B.; Anto, J. M; Cardona, V.; Mullol, J.; Pinnock, H.; Ryan, D.; Sheikh, A.; Walker, S.; Williams, S.; Becker, S.; Klimek, L.; Pfaar, O.; Bergmann, K. C; Mösges, R.; Zuberbier, T.; Roller-Wirnsberger, R. E; Tomazic, P. V; Haahtela, T.; Salimäki, J.; Toppila-Salmi, S.; Valovirta, E.; Vasankari, T.; Gemicioğlu, B.; Yorgancioglu, A.; Papadopoulos, N. G; Prokopakis, E. P; Tsiligianni, I. G; Bosnic-Anticevich, S.; O’Hehir, R.; Ivancevich, J. C; Neffen, H.; Zernotti, M. E; Kull, I.; Melén, E.; Wickman, M.; Bachert, C.; Hellings, P. W; Brusselle, G.; Palkonen, S.; Bindslev-Jensen, C.; Eller, E.; Waserman, S.; Boulet, L. P; Bouchard, J.; Chu, D. K; Schünemann, H. J; Sova, M.; De Vries, G.; van Eerd, M.; Agache, I.; Ansotegui, I. J; Bewick, M.; Casale, T.; Dykewick, M.; Ebisawa, M.; Murray, R.; Naclerio, R.; Okamoto, Y.; Wallace, D. V (BioMed Central, 2019)
    Abstract Aims Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders Include patients, health care professionals (pharmacists and physicians), authorities, patient’s associations, private and public sectors. Results MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018) MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.
  • Vandenplas, O.; Vinnikov, D.; Blanc, P. D.; Agache, I.; Bachert, C.; Bewick, M.; Cardell, L. O.; Cullinan, P.; Demoly, P.; Descatha, A.; Fonseca, J.; Haahtela, T.; Hellings, P.W.; Jamart, J.; Jantunen, J.; Kalayci, Ö.; Price, D.; Samolinski, B.; Sastre, J.; Tian, L.; Valero, A. L.; Zhang, X.; Bousquet, J. (2018)
    BACKGROUND: Allergic rhinitis (AR) is increasingly acknowledged as having a substantial socioeconomic impact associated with impaired work productivity, although available information remains fragmented. OBJECTIVE: This systematic review summarizes recently available information to provide a quantitative estimate of the burden of AR on work productivity including lost work time (ie, absenteeism) and reduced performance while working (ie, presenteeism). METHODS: A Medline search retrieved original studies from 2005 to 2015 pertaining to the impact of AR on work productivity. A pooled analysis of results was carried out with studies reporting data collected through the validated Work Productivity and Activity Impairment (WPAI) questionnaire. RESULTS: The search identified 19 observational surveys and 9 interventional studies. Six studies reported economic evaluations. Pooled analysis of WPAI-based studies found an estimated 3.6% (95% confidence interval [CI], 2.4; 4.8%) missed work time and 35.9% (95% CI, 29.7; 42.1%) had impairment in at-work performance due to AR. Economic evaluations indicated that indirect costs associated with lost work productivity are the principal contributor to the total AR costs and result mainly from impaired presenteeism. The severity of AR symptoms was the most consistent disease-related factor associated with a greater impact of AR on work productivity, although ocular symptoms and sleep disturbances may independently affect work productivity. Overall, the pharmacologic treatment of AR showed a beneficial effect on work productivity. CONCLUSIONS: This systematic review provides summary estimates of the magnitude of work productivity impairment due to AR and identifies its main determinant factors. This information may help guide both clinicians and health policy makers. (C) 2017 American Academy of Allergy, Asthma & Immunology
  • Toppila-Salmi, Sanna; Rihkanen, Heikki; Mäkelä, Mika; Klockars, Tuomas (2018)
  • MASK Study Grp (2018)
    mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), the Phase 3 ARIA initiative, is based on the freely available MASK app (the Allergy Diary, Android and iOS platforms). MASK is available in 16 languages and deployed in 23 countries. The present paper provides an overview of the methods used in MASK and the key results obtained to date. These include a novel phenotypic characterization of the patients, confirmation of the impact of allergic rhinitis on work productivity and treatment patterns in real life. Most patients appear to self-medicate, are often non-adherent and do not follow guidelines. Moreover, the Allergy Diary is able to distinguish between AR medications. The potential usefulness of MASK will be further explored by POLLAR (Impact of Air Pollution on Asthma and Rhinitis), a new Horizon 2020 project using the Allergy Diary.
  • Bousquet, Jean; Ansotegui, Ignacio J.; Anto, Josep M.; Arnavielhe, Sylvie; Bachert, Claus; Basagana, Xavier; Bedard, Annabelle; Bedbrook, Anna; Bonini, Matteo; Bosnic-Anticevich, Sinthia; Braido, Fulvio; Cardona, Vicky; Czarlewski, Wienczyslawa; Cruz, Alvaro A.; Demoly, Pascal; De Vries, Govert; Dramburg, Stephanie; Mathieu-Dupas, Eve; Erhola, Marina; Fokkens, Wytske J.; Fonseca, Joao A.; Haahtela, Tari; Hellings, Peter W.; Illario, Maddalena; Ivancevich, Juan Carlos; Jormanainen, Vesa; Klimek, Ludger; Kuna, Piotr; Kvedariene, Violeta; Laune, Daniel; Larenas-Linnemann, Desiree; Lourenco, Olga; Onorato, Gabrielle L.; Matricardi, Paolo M.; Melen, Erik; Mullol, Joaquim; Papadopoulos, Nikos G.; Pfaar, Oliver; Nhan Pham-Thi,; Sheikh, Aziz; Tan, Rachel; To, Teresa; Tomazic, Peter Valentin; Toppila-Salmi, Sanna; Tripodi, Salvadore; Wallace, Dana; Valiulis, Arunas; van Eerd, Michiel; Ventura, Maria Teresa; Yorgancioglu, Arzu; Zuberbier, Torsten (2019)
    Smart devices and Internet-based applications (apps) are largely used in allergic rhinitis and may help to address some unmet needs. However, these new tools need to first of all be tested for privacy rules, acceptability, usability, and cost-effectiveness. Second, they should be evaluated in the frame of the digital transformation of health, their impact on health care delivery, and health outcomes. This review (1) summarizes some existing mobile health apps for allergic rhinitis and reviews those in which testing has been published, (2) discusses apps that include risk factors of allergic rhinitis, (3) examines the impact of mobile health apps in phenotype discovery, (4) provides real-world evidence for care pathways, and finally (5) discusses mobile health tools enabling the digital transformation of health and care, empowering citizens, and building a healthier society. (C) 2019 American Academy of Allergy, Asthma & Immunology
  • Toppila-Salmi, Sanna; van Drunen, Cornelis M.; Fokkens, Wytske J.; Golebski, Korneliuz; Mattila, Pirkko; Joenvaara, Sakari; Renkonen, Jutta; Renkonen, Risto (2015)
  • ARIA Study Grp; MASK Study Grp; Bousquet, J. Jean; Schunemann, Holger J.; Togias, Alkis; Haahtela, Tari; Toppila-Salmi, Sanna (2019)
    Background In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Sante as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.
  • Hisinger-Mölkänen, Hanna; Piirilä, Päivi; Haahtela, Tari; Sovijärvi, Anssi; Pallasaho, Paula (2018)
    Background: Allergic and non-allergic rhinitis cause a lot of symptoms in everyday life. To decrease the burden more information of the preventable risk factors is needed. We assessed prevalence and risk factors for chronic nasal symptoms, exploring the effects of smoking, environmental tobacco smoke, exposure to occupational irritants, and their combinations. Methods: In 2016, a postal survey was conducted among a random population sample of 8000 adults in Helsinki, Finland with a 50.5% response rate. Results: Smoking was associated with a significant increase in occurrence of chronic rhinitis (longstanding nasal congestion or runny nose), but not with self-reported or physician diagnosed allergic rhinitis. The highest prevalence estimates of nasal symptoms, 55.1% for chronic rhinitis, 49.1% for nasal congestion, and 40.7% for runny nose, were found among smokers with occupational exposure to gases, fumes or dusts. Besides active smoking, also exposure to environmental tobacco smoke combined with occupational exposure increased the risk of nasal symptoms. Conclusions: Smoking, environmental tobacco smoke, and occupational irritants are significant risk factors for nasal symptoms with an additive pattern. The findings suggest that these factors should be systematically inquired in patients with nasal symptoms for appropriate preventive measures. (192 words).
  • Hytönen, Maija; Hammarén-Malmi, Sari; Myller, Jyri; Mäkelä, Marjukka; Penttilä, Elina; Pessi, Timo; Puhakka, Tuomo; Raappana, Antti; Taulu, Rami; Toppila-Salmi, Sanna; Virkkula, Paula (2017)
  • Hemila, Harri; Chalker, Elizabeth (2015)
    BACKGROUND: A previous meta-analysis found that high dose zinc acetate lozenges reduced the duration of common colds by 42%, whereas low zinc doses had no effect. Lozenges are dissolved in the pharyngeal region, thus there might be some difference in the effect of zinc lozenges on the duration of respiratory symptoms in the pharyngeal region compared with the nasal region. The objective of this study was to determine whether zinc acetate lozenges have different effects on the duration of common cold symptoms originating from different anatomical regions. METHODS: We analyzed three randomized trials on zinc acetate lozenges for the common cold administering zinc in doses of 80-92 mg/day. All three trials reported the effect of zinc on seven respiratory symptoms, and three systemic symptoms. We pooled the effects of zinc lozenges for each symptom and calculated point estimates and 95% confidence intervals (95% CI). RESULTS: Zinc acetate lozenges shortened the duration of nasal discharge by 34% (95% CI: 17% to 51%), nasal congestion by 37% (15% to 58%), sneezing by 22% (-1% to 45%), scratchy throat by 33% (8% to 59%), sore throat by 18% (-10% to 46%), hoarseness by 43% (3% to 83%), and cough by 46% (28% to 64%). Zinc lozenges shortened the duration of muscle ache by 54% (18% to 89%), but there was no difference in the duration of headache and fever. CONCLUSIONS: The effect of zinc acetate lozenges on cold symptoms may be associated with the local availability of zinc from the lozenges, with the levels being highest in the pharyngeal region. However our findings indicate that the effects of zinc ions are not limited to the pharyngeal region. There is no indication that the effect of zinc lozenges on nasal symptoms is less than the effect on the symptoms of the pharyngeal region, which is more exposed to released zinc ions. Given that the adverse effects of zinc in the three trials were minor, zinc acetate lozenges releasing zinc ions at doses of about 80 mg/day may be a useful treatment for the common cold, started within 24 hours, for a time period of less than two weeks.
  • Valiulis, A.; Bousquet, J.; Veryga, A.; Suprun, U.; Sergeenko, D.; Cebotari, S.; Borelli, D.; Pietikainen, S.; Banys, J.; Agache, I.; Billo, N. E.; Bush, A.; Chkhaidze, I.; Dubey, L.; Fokkens, W. J.; Grigg, J.; Haahtela, T.; Julge, K.; Katilov, O.; Khaltaev, N.; Odemyr, M.; Palkonen, S.; Savli, R.; Utkus, A.; Vilc, V.; Alasevicius, T.; Bedbrook, A.; Bewick, M.; Chorostowska-Wynimko, J.; Danila, E.; Hadjipanayis, A.; Karseladze, R.; Kvedariene, V.; Lesinskas, E.; Munter, L.; Samolinski, B.; Sargsyan, S.; Sitkauskiene, B.; Somekh, D.; Vaideliene, L.; Valiulis, A.; Hellings, P. W. (2019)
    Background: Over 1 billion people suffer from chronic respiratory diseases such as asthma, COPD, rhinitis and rhinosinusitis. They cause an enormous burden and are considered as major non-communicable diseases. Many patients are still uncontrolled and the cost of inaction is unacceptable. A meeting was held in Vilnius, Lithuania (March 23, 2018) under the patronage of the Ministry of Health and several scientific societies to propose multisectoral care pathways embedding guided self-management, mHealth and air pollution in selected chronic respiratory diseases (rhinitis, chronic rhinosinusitis, asthma and COPD). The meeting resulted in the Vilnius Declaration that was developed by the participants of the EU Summit on chronic respiratory diseases under the leadership of Euforea. Conclusion: The Vilnius Declaration represents an important step for the fight against air pollution in chronic respiratory diseases globally and has a clear strategic relevance with regard to the EU Health Strategy as it will bring added value to the existing public health knowledge.